With the US economy shedding 23,000 jobs in July and inflation still elevated, investors are watching consumer wallets more closely. That mix can punish some areas of the market while creating interest in larger consumer staples stocks that often sit closer to everyday spending. This article walks through three such companies from a dedicated screener and explains how their exposure to these trends could matter for your portfolio decisions.

The three stocks highlighted below are just a sample, and the full screen surfaced 13 more large consumer staples companies with equally compelling narratives that are not covered in this article. To get straight to the source, head into the Consumer Staples Stocks screener to identify and analyze the highest conviction ideas that match your own criteria.

a2 Milk (NZSE:ATM)

a2 Milk sells A2 protein milk and infant formula under the a2 Milk and a2 Platinum brands across Australia, New Zealand, China, the rest of Asia and the US, with a strong focus on early life and specialty nutrition. Most revenue comes from China and other Asian markets at about NZ$1.43b, followed by Australia and New Zealand at about NZ$328 million and the US at about NZ$158 million, with a smaller segment adjustment item. The company has a market value of roughly NZ$6.0b.

Investors looking at a2 Milk are weighing a sizeable China centric infant formula business and solid earnings quality against a mixed picture on valuation, competition and operational risk. Earnings have grown at high single digits historically and are forecast to grow at mid teens rates, while profit margins and projected return on equity are expected to improve. At the same time, the stock trades well above some fair value estimates and industry P/E averages. The recent US Class I recall of certain infant formula batches and reliance on higher cost freight show how execution missteps or supply issues can affect margins and brand trust. In parallel, new product lines, expansion in Asia and ongoing research on A2 protein benefits keep the story in motion and make this a business that some investors may consider looking at more closely beyond the headlines.

a2 Milk’s earnings story and China exposure can look strong on the surface, yet the real tension sits between growth hopes and what investors are paying today. Before you decide how that trade off stacks up, walk through the analyst forecasts for a2 Milk to see what the current numbers might be hinting at but not fully revealing.

Build your own growth focused shortlist around a2 Milk

a2 Milk and the two other stocks in this article all came out of a single custom screen, which shows how much ground you can cover with the right filters. Use our flexible Screener to mix metrics like valuation, future growth, quality and risks to match your style, or start with any of our curated Investing Ideas.

Lifeway Foods (LWAY)

Lifeway Foods produces probiotic dairy products led by drinkable kefir, alongside European style soft cheeses, drinkable yogurt, kids focused ProBugs lines, and other cultured dairy items sold under the Lifeway, Fresh Made, GlenOaks Farms and private label brands. The business currently generates about US$229 million in revenue entirely from cultured dairy products, with all reported sales coming from the United States, and carries a market value of roughly US$481 million.

Investors watching consumer staples during weaker job data and sticky inflation may find Lifeway Foods interesting because it sits at the intersection of everyday refrigerated staples and gut health trends, supported by expanding retail distribution and higher margin functional products like collagen infused kefir. At the same time, the company remains heavily reliant on dairy based kefir and a concentrated retailer base, while recent governance debates, insider selling and a fresh equity capital raise leave questions about earnings quality and how much credit the stock should get for its growth and margin ambitions.

Lifeway Foods sits at a crossroads of gut health trends and governance questions. Before the story runs too far ahead of the fundamentals, walk through the 3 key rewards and 2 important warning signs (1 is major!) that could shift how you frame the next move.

Vita Coco Company (COCO)

The Vita Coco Company develops, manufactures and sells coconut based drinks and dairy alternatives like Vita Coco coconut water, pressed blends, coconut milk and protein infused PWR LIFT across the Americas, Europe and Asia Pacific. Most revenue comes from the Americas at about US$575 million, with the international segment adding roughly US$131 million. The stock sits in mid cap territory with a market value of about US$3.8b.

Vita Coco Company gives you a pure play on coconut based hydration and wellness at a time when many consumers are watching everyday spending but still paying up for trusted staples and better for you drinks. The business is growing through product extensions, international expansion and the recently announced Copra acquisition. Together, these developments set expectations for higher scale and potentially stronger margins as supply chain changes bed in. On the flip side, heavy reliance on coconut sourcing from a few regions, tariff and freight cost swings, plus exposure to private label contracts create real earnings risk if conditions turn. With high returns on equity and rising profitability on one hand, and concentrated category and cost pressures on the other, this is a company that rewards closer study rather than a quick headline skim.

Vita Coco’s growth story, category focus and new Copra deal all hint at something investors may be underpricing. Before you assume the market has it figured out, walk through the analyst forecasts for Vita Coco Company and see what might be quietly building under the surface.

Seeking Fresh Alternatives Before They Fly

Some of the sharpest breakouts start quietly, while momentum builds under the radar for now. Use these fresh idea lists before the crowd catches on and act now.

• Spot sturdy compounding potential by reviewing a hand picked list of solid balance sheet and fundamentals (422 results) that may hold companies ready to keep moving while their fundamentals still look robust.
• Ride early momentum in income ideas by scanning curated 439 dividend fortresses that could keep paying investors while yields stay elevated and prices have not fully caught up.
• Get ahead of future infrastructure shifts by tracking focused 36 power grid technology and infrastructure stocks where demand trends might build long before prices reflect the full story.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.